Background Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …

Background Colistin–carbapenem combinations are synergistic in vitro against carbapenem-
resistant Gram-negative bacteria. We aimed to test whether combination therapy improves …

Objectives In vitro models showing synergism between polymyxins and carbapenems
support combination treatment for carbapenem-resistant Gram-negative (CRGN) infections …

Objectives In clinical practice, colistin is used as combination therapy to improve its
antibacterial activity, despite the consequent increase in toxicity. This prospective …

Carbapenem-resistant Acinetobacter baumannii (CRAB), an important nosocomial
pathogen, occurs particularly in the intensive care unit (ICU). Thus, the aim of this study was …

Background We evaluated the association between mortality and colistin resistance in
Acinetobacter baumannii infections and the interaction with antibiotic therapy. Methods This …

Objectives The aim of this study was to confirm the synergistic effect of colistin/rifampicin
combination therapy compared with colistin monotherapy in pneumonia caused by colistin …

Ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) Gram-
negative bacteria (GNB) has emerged as an important and intractable clinical problem. This …

Background Antimicrobial resistance is an increasingly serious threat to public health, and
the increased occurrence of multidrug-resistant (MDR) bacteria is a concern in both high …

Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) is one of the
most commonly found nosocomial infections in critically ill patients. However, the …